☰

Luca Gambini - Publications

Affiliations: 
2015-2016 Chemistry University of California, Riverside, Riverside, CA, United States 
Tree Info Similar researchers PubMed Report error

18 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Baggio C, Udompholkul P, Gambini L, Pellecchia M. Targefrin: A Potent Agent Targeting the Ligand Binding Domain of EphA2. Journal of Medicinal Chemistry. PMID 36331527 DOI: 10.1021/acs.jmedchem.2c01391  0.42
2021 Udompholkul P, Baggio C, Gambini L, Alboreggia G, Pellecchia M. Lysine Covalent Antagonists of Melanoma Inhibitors of Apoptosis Protein. Journal of Medicinal Chemistry. 64: 16147-16158. PMID 34705456 DOI: 10.1021/acs.jmedchem.1c01459  0.385
2021 Udompholkul P, Baggio C, Gambini L, Sun Y, Zhao M, Hoffman RM, Pellecchia M. Effective Tumor Targeting by EphA2-Agonist-Biotin-Streptavidin Conjugates. Molecules (Basel, Switzerland). 26. PMID 34204178 DOI: 10.3390/molecules26123687  0.344
2021 Gambini L, Udompholkul P, Baggio C, Muralidharan A, Kenjić N, Assar Z, Perry JJP, Pellecchia M. Design, Synthesis, and Structural Characterization of Lysine Covalent BH3 Peptides Targeting Mcl-1. Journal of Medicinal Chemistry. 64: 4903-4912. PMID 33797903 DOI: 10.1021/acs.jmedchem.1c00005  0.406
2020 Gambini L, Udompholkul P, Salem AF, Baggio C, Pellecchia M. Stability and cell permeability of sulfonyl fluorides in the design  of Lys-covalent antagonists of protein-protein interactions. Chemmedchem. PMID 32790900 DOI: 10.1002/Cmdc.202000355  0.434
2020 Barile E, Baggio C, Gambini L, Shiryaev SA, Pellecchia AYSAM. Potential Therapeutic Targeting of Coronavirus Spike Glycoprotein Priming. Molecules (Basel, Switzerland). 25. PMID 32455942 DOI: 10.3390/Molecules25102424  0.38
2020 Salem AF, Gambini L, Udompholkul P, Baggio C, Pellecchia M. Therapeutic Targeting of Pancreatic Cancer via EphA2 Dimeric Agonistic Agents. Pharmaceuticals (Basel, Switzerland). 13. PMID 32397624 DOI: 10.3390/Ph13050090  0.451
2020 Baggio C, Udompholkul P, Gambini L, Jossart J, Salem AF, Håkansson M, Perry JJP, Pellecchia M. N-locking stabilization of covalent helical peptides: Application to Bfl-1 antagonists. Chemical Biology & Drug Design. PMID 31898401 DOI: 10.1111/Cbdd.13661  0.36
2019 Baggio C, Udompholkul P, Gambini L, Salem AF, Jossart J, Perry JJP, Pellecchia M. Aryl-fluorosulfate-based Lysine Covalent pan-Inhibitors of Apoptosis Proteins (IAP) Antagonists with Cellular Efficacy. Journal of Medicinal Chemistry. PMID 31550155 DOI: 10.1021/Acs.Jmedchem.9B01108  0.475
2019 Gambini L, Baggio C, Udompholkul P, Jossart J, Salem AF, Perry JJP, Pellecchia M. Covalent Inhibitors of Protein-Protein Interactions Targeting Lysine, Tyrosine, or Histidine Residues. Journal of Medicinal Chemistry. PMID 31095386 DOI: 10.1021/Acs.Jmedchem.9B00561  0.488
2018 Gambini L, Salem AF, Udompholkul P, Tan XF, Baggio C, Shah N, Aronson A, Song J, Pellecchia M. Structure-based design of novel EphA2 agonistic agents with nanomolar affinity in vitro and in cell. Acs Chemical Biology. PMID 30110533 DOI: 10.1021/Acschembio.8B00556  0.489
2018 Baggio C, Gambini L, Udompholkul P, Salem AF, Aronson A, Dona A, Troadec E, Pichiorri F, Pellecchia M. Design of Potent pan-IAP and Lys-Covalent XIAP selective Inhibitors Using a Thermodynamics Driven Approach. Journal of Medicinal Chemistry. PMID 29940121 DOI: 10.1021/Acs.Jmedchem.8B00810  0.472
2018 Salem AF, Wang S, Billet S, Chen JF, Udompholkul P, Gambini L, Baggio C, Tseng HR, Posadas EM, Bhowmick NA, Pellecchia M. A potent EphA2 agonistic peptide-drug conjugate reduces circulating cancer cells and metastases in breast cancer models. Journal of Medicinal Chemistry. PMID 29470068 DOI: 10.1021/Acs.Jmedchem.7B01837  0.422
2016 Barile E, Marconi GD, De SK, Baggio C, Gambini L, Salem AF, Kashyap MK, Castro JE, Kipps TJ, Pellecchia M. hBfl-1/hNOXA Interaction Studies Provide New Insights on the Role of Bfl-1 in Cancer Cell Resistance and for the Design of Novel Anticancer Agents. Acs Chemical Biology. PMID 28026162 DOI: 10.1021/Acschembio.6B00962  0.494
2016 Avvakumova S, Galbiati E, Sironi L, Locarno SA, Gambini L, Macchi C, Pandolfi L, Ruscica M, Magni P, Collini M, Colombo M, Corsi F, Chirico G, Romeo S, Prosperi D. Theranostic Nanocages for Imaging and Photothermal Therapy of Prostate Cancer Cells by Active Targeting of Neuropeptide-Y Receptor. Bioconjugate Chemistry. 27: 2911-2922. PMID 27809498 DOI: 10.1021/Acs.Bioconjchem.6B00568  0.403
2016 Galbiati E, Gambini L, Civitarese V, Bellini M, Ambrosini D, Allevi R, Avvakumova S, Romeo S, Prosperi D. "Blind" targeting in action: From phage display to breast cancer cell targeting with peptide-gold nanoconjugates. Pharmacological Research. 111: 155-162. PMID 27293049 DOI: 10.1016/J.Phrs.2016.06.007  0.429
2015 Gambini L, Rizzi L, Pedretti A, Taglialatela-Scafati O, Carucci M, Pancotti A, Galli C, Read M, Giurisato E, Romeo S, Russo I. Picomolar Inhibition of Plasmepsin V, an Essential Malaria Protease, Achieved Exploiting the Prime Region. Plos One. 10: e0142509. PMID 26566224 DOI: 10.1371/Journal.Pone.0142509  0.396
2015 Pancotti A, Parapini S, Dell'Agli M, Gambini L, Galli C, Sangiovanni E, Basilico N, Bosisio E, Taramelli D, Romeo S. Discovery of oxybisbenzoylamides as a new class of antimalarial agents Medchemcomm. 6: 1173-1177. DOI: 10.1039/C5Md00115C  0.355
Show low-probability matches.